Group 1 - The company Tianjin Development (00882) reported its indirect non-wholly-owned subsidiary Tianjin Lisheng Pharmaceutical Co., Ltd. (Lisheng Pharmaceutical) financial results for the six months ending June 30, 2025, with total revenue of 732 million RMB, a year-on-year decrease of 1.76% [1] - The net profit attributable to the parent company was 343 million RMB, representing a significant year-on-year increase of 235.04% [1] - The basic earnings per share were reported at 1.33 RMB [1]

( 於香港註冊成立之有限公司 ) 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份 內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 (股份代號：882) 天津力生製藥股份有限公司 截至二零二五年六月三十日止六個月之 未經審核財務業績 本公告乃天津發展控股有限公司(「本公司」)根據證券及期貨條例(香港法例第 571章)第XIVA部及香港聯合交易所有限公司證券上市規則第13.09條而作出， 向本公司股東及公眾人士提供其間接非全資附屬公司天津力生製藥股份有限公 司(「力生製藥」)截至二零二五年六月三十日止六個月之未經審核合併財務業 績。 力生製藥乃一間於中華人民共和國成立的公司，其股份於深圳證券交易所上市。 於本公告日期，本公司間接持有力生製藥約34.11%之已發行股本。根據中國企 業會計準則而編制之力生製藥截至二零二五年六月三十日止六個月之未經審核 合併利潤表及於二零二五年六月三十日之未經審核簡明合併資產負債表載列如 下： - 1 - 天津力生製藥股份有限公司 合併利潤表 截至二零二五年六月三十日止六個 ...

Group 1 - Tianjin Development (00882) announced that its indirect non-wholly-owned subsidiary, Lifesun Pharmaceutical (002393), plans to establish a fund with several partners, including Jianxin Equity and Teda Private Equity, with a proposed total subscription amount of RMB 500 million [1] - Lifesun Pharmaceutical intends to contribute RMB 174 million to the fund, representing 34.75% of the total proposed subscription amount [1] - The fund, tentatively named Jian Sheng Guo Xin Tai Da Equity Fund Partnership (Limited Partnership), is proposed to have a duration of five years and will primarily invest in the health and biotechnology sectors in China [1] Group 2 - The board believes that the potential transaction, if realized, will help the group deepen its understanding of the latest industry developments in the pharmaceutical sector, diversify investment risks, and identify potential strategic partners for future opportunities [1] - The board also considers that the investment in the fund could provide more industry acquisition opportunities aligned with the company's development strategy, offering potential returns beyond fixed income and improving capital allocation efficiency [1]

Core Viewpoint - Tianjin Development (00882) announced that its indirect non-wholly owned subsidiary, Lisheng Pharmaceutical, plans to establish a fund with several partners, aiming to raise a total of RMB 500 million, with Lisheng contributing RMB 174 million, representing 34.75% of the total fund [1] Group 1: Fund Establishment - The fund, tentatively named Jian Sheng Guo Xin Tai Da Equity Fund Partnership (Limited Partnership), has a proposed duration of five years [1] - The fund will primarily invest in the health and biotechnology sectors in China [1] Group 2: Strategic Implications - The potential transaction, if realized, is expected to enhance the group's understanding of the latest developments in the pharmaceutical industry, diversify investment risks, and identify potential strategic partners for future opportunities [1] - The group's investment in the fund is anticipated to provide more industry acquisition opportunities aligned with its development strategy and offer potential returns exceeding fixed income, thereby improving capital allocation efficiency and enhancing capital returns [1]

Group 1 - Company Tianjin Development (00882.HK) announced its indirect subsidiary, Lisheng Pharmaceutical (002393.SZ), plans to establish a fund with several partners, with a proposed total subscription amount of RMB 500 million [1] - Lisheng Pharmaceutical intends to contribute RMB 173.75 million, representing 34.75% of the total proposed subscription amount for the fund [1] - The fund, tentatively named Jian Sheng Guo Xin Tai Da Equity Fund Partnership (Limited Partnership), aims to invest in the health and biotechnology sectors in China [1] Group 2 - The board believes that the potential transaction will enhance the group's understanding of the latest developments in the pharmaceutical industry, diversify investment risks, and identify potential strategic partners for future opportunities [2] - The group's investment in the fund is expected to provide more industry acquisition opportunities aligned with its development strategy and offer potential returns exceeding fixed income, thereby improving capital allocation efficiency and returns [2]

Group 1 - The company Tianjin Development (00882.HK) announced its indirect subsidiary, Lisheng Pharmaceutical (002393.SZ), plans to establish a fund with a total proposed subscription amount of RMB 500 million, with Lisheng contributing RMB 173.75 million, accounting for 34.75% of the total [1] - The fund, tentatively named Jian Sheng Guo Xin Tai Da Equity Fund Partnership (Limited Partnership), has a proposed duration of five years and will primarily invest in the health and biotechnology sectors in China [1] - The establishment of this fund is expected to deepen the company's understanding of the latest developments in the pharmaceutical industry, diversify investment risks, and identify potential strategic partners for future opportunities [2] Group 2 - The company believes that investing in the fund will provide more industry acquisition opportunities aligned with its development strategy and offer potential returns beyond fixed income, thereby improving capital allocation efficiency and enhancing capital returns [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份 內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於香港註冊成立之有限公司） （股份代號： 882） 潛在須予披露及關連交易 設立基金 董事會宣佈，力生製藥（本公司間接非全資附屬公司）擬與建信股權、泰達 私募、共青城建興、泰達國際、國資母基金及戰新基金就設立基金訂立合夥 協議，該基金的建議認繳出資總額為人民幣500,000,000元（相當於約港幣 547,045,952元），其中，力生製藥擬向該基金認繳出資人民幣173,750,000元 （相當於約港幣190,098,468元），佔該基金建議認繳出資總額的34.75%，惟 須受合夥協議的條款及條件所規限。 由於根據上市規則第14.07條計算有關潛在交易的最高適用百分比率超過 5%，但概無適用百分比率超過25%，故潛在交易（倘落實）將構成本公司 的一項須予披露交易，並須遵守上市規則第14章項下的申報及公告規定。 於本公告日期，泰達控股透過其若干附屬公司（包括渤海國資）間接持有已 發行股份總數約62.81 ...

Group 1 - The company Tianjin Development (00882.HK) announced that it will hold a board meeting on August 28, 2025, to approve the release of its interim results for the six months ending June 30, 2025 [1] - The board meeting will also consider the distribution of an interim dividend, if applicable [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於香港註冊成立之有限公司） 董事會召開日期 天津發展控股有限公司（「 本公司 」）董事會（「 董事會 」）謹此 宣佈，本公司將於二零二五年八月二 十八日（星期四）舉行董事會 會議，藉以（其中包括）批准 發佈本公司及其附屬公司截至 二零二五年六月三十日止六個月之中 期業績公告，以及考慮派發中 期股息（如有）。 承董事會命 天津發展控股有限公司 主席及執行董事 滕 飛 香港，二零二五年八月十八日 於本公告日期，本公司董事會包括滕飛先生、翟欣翔博士、夏濱輝先生、 孫利軍先生 * 、伍綺琴女士 ** 、黃紹開先生 ** 、樓家強先生 ** 及 冼漢廸先生 ** 。 * 非執行董事 ** 獨立非執行董事 （股份代號： 882） ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年7月31日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 天津發展控股有限公司 | | | 呈交日期: | 2025年8月1日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00882 | 說明 | | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | | 1,072,770,125 | | 0 | | 1,072,770,125 | | 增加 / 減少 ...